Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer's disease

References

• Brys M, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging 2009;30:682–90.
   PubMed Web of Science ®Google Scholar
• Dumurgier J, Mouton-Liger F, Lapalus P, et al. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease. PLoS ONE 2013;8:e53587.
   PubMedGoogle Scholar
• Kester MI, Scheffer PG, Koel-Simmelink MJ, et al. Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiol Aging 2012;33:1591–8.
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen HH, Li TL, et al. A cross-sectional study on cerebrospinal fluid biomarker levels in cognitively elderly subjects with or without a family history of Alzheimer's disease. CNS Neurosci Ther 2013;19:38–42.
   PubMed Web of Science ®Google Scholar
• Markesbery WR, Kryscio RJ, Lovell MA, et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 2005;58:730–5.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ, Roberts LJ 2nd. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791–800.
   PubMed Web of Science ®Google Scholar
• Basu S. Isoprostanes: novel bioactive products of lipid peroxidation. Free Radic Res 2004;38:105–22.
   PubMed Web of Science ®Google Scholar
• Praticò D. Alzheimer's disease and oxygen radicals: new insights. Biochem Pharmacol 2002;63:563–7.
   PubMed Web of Science ®Google Scholar
• Casadesus G, Smith MA, Basu S, et al. Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener 2007;2:2.
   PubMed Web of Science ®Google Scholar
• Roberts LJ 2nd, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Bio Chem 1998;273:13605–12.
   PubMed Web of Science ®Google Scholar
• Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566–72.
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. ‘Mini-Mental State’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975;12:189–98.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–8.
   PubMed Web of Science ®Google Scholar
• Wang HM, Yang CM, Kuo WC, et al. Use of a modified spatial-context memory test to detect amnestic mild cognitive impairment. PLoS ONE 2013;8(2):e57030. doi:10.1371/journal.pone.0057030.
   PubMed Web of Science ®Google Scholar
• Huang KL, Lin KJ, Hsiou IT, et al. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS ONE 2013;8:e58974.
   PubMedGoogle Scholar
• Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989;39:1159–65.
   PubMed Web of Science ®Google Scholar
• Chuang WL, Wang HM, Hsieh YC, et al. Visual association memory test in differentiating early stage of Alzheimer's disease from vascular dementia. Acta Neurol Taiwan 2006;15:98–104.
   PubMedGoogle Scholar
• Hsieh YP, Lin CL, Shiue AL, et al. Correlation of F4-neuroprostanes levels in cerebrospinal fluid with outcome of aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2009;47:814–24.
   PubMed Web of Science ®Google Scholar
• Milne GL, Yin H, Brooks JD, et al. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007;433:113–26.
   PubMed Web of Science ®Google Scholar
• van Harten AC, Visser PJ, Pijnenburg YA, et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 2013;9:481–7.
   PubMed Web of Science ®Google Scholar
• Van Hoesen GW, Parvizi J, Chu CC. Orbitofrontal cortex pathology in Alzheimer's disease. Cereb Cortex 2000; 10:243–51.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Frequency of stages in Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351–7.
   PubMed Web of Science ®Google Scholar
• Montine KS, Quinn JF, Zhang J, et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipid 2004;128:117–24.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Markesbery WR, Morrow JD, et al. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol 1998;44:410–3.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Beal MF, Cudkowicz ME, et al. Increased cerebrospinal fluid F2-isoprostane concentration in probable Alzheimer's disease. Neurology 1999;52:562–5.
   PubMed Web of Science ®Google Scholar
• Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostane and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 2002;52:175–9.
   PubMed Web of Science ®Google Scholar
• Reich EE, Markesbery WR, Roberts LJ 2nd, et al. Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am J Pathol 2001;158:293–7.
   PubMed Web of Science ®Google Scholar
• Pomara N, Bruno D, Sarreal AS, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012;169:523–30.
   PubMed Web of Science ®Google Scholar
• Coccaro EF, Lee R, Gozal D. Elevated plasma oxidative stress markers in individuals with intermittent explosive disorder and correlation with aggression in humans. Biol Psychiatry 2014;pii:S0006-3223(14):00053–5. doi: 10.1016/j.biopsych.2014.01.014. [Epub ahead of print]
   Google Scholar
• Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry 2010;67:584–587.
   PubMed Web of Science ®Google Scholar
• Shinosaki K, Nishikawa T, Takeda M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci 2000;54:611–20.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhukareva V, Sung S, et al. Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia. Neurology 2003;61:475–8.
   PubMed Web of Science ®Google Scholar